By Jamie Reno, June 15, 2022

BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free DNA (cfDNA), and/or exosomes, which are particles that release naturally from a cell.

Rolf Muller, the company’s chief executive officer, noted that the technologies developed by BioFluidica can be used to determine if a person with cancer is a candidate for targeted therapy.

Read the Entire Article Here